Clinical trials recruiting for Advanced Melanoma
23
Recruiting trials
35
US states with sites
33
Countries
4%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Florida | 6 |
| New Jersey | 5 |
| New York | 5 |
| Texas | 5 |
| Arizona | 4 |
| California | 4 |
| Missouri | 4 |
| Ohio | 4 |
| Pennsylvania | 4 |
| Colorado | 3 |
| Connecticut | 3 |
| Kansas | 3 |
Top cities
Houston, Texas 4Jacksonville, Florida 4Los Angeles, California 4New York, New York 4Pittsburgh, Pennsylvania 4St Louis, Missouri 4Boston, Massachusetts 3Columbus, Ohio 3Hackensack, New Jersey 3Knoxville, Tennessee 3
Self-screener
Recruiting trials
- A Clinical Study of T3011 in Subjects With Advanced Melanoma
- A Phase II Trial of LM103 in Advanced Melanoma
- A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
- A Study of GC101 TIL in Advanced Melanoma (10hospital)
- A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma
- AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
- At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
- Au-TMP and Radiotherapy for Advanced Melanoma With Anti-PD-1 Therapy
- FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
- High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial
- IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
- IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
- Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors
- Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
- NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma
- Naltrexone and Propranolol Combined With Immunotherapy
- Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
- Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)
- Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
- Sitagliptin With Pembro in RCC and Melanoma
- Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
- VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
- ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
Related conditions
Trials recruiting for Advanced Melanoma often also study these conditions. Each links to its own recruiting-trial list.
Melanoma 487Metastatic Melanoma 40Advanced Renal Cell Carcinoma 6Advanced Malignant Solid Neoplasm 13Lung cancer 2180Advanced Hepatocellular Carcinoma 4Advanced Head and Neck Squamous Cell Carcinoma 3Advanced Endometrial Carcinoma 4Advanced Biliary Tract Carcinoma 4Treatment Side Effects 6
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Advanced Melanoma trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.